• Slide 1/4: Woman with hands on stomach overlaid with "maltol shield" inside stomach imagery
  • Slide 2/4: Main smiling overlaid with ACCRUFeR pill bottle
  • Slide 3/4: Woman smiling with arms crossed overlaid with "maltol shield" inside stomach imagery
  • Slide 4/4: Woman with arms crossed overlaid with ACCRUFeR pill bottle

Iron They'll Actually Take

ACCRUFeR®(ferric maltol) has a unique “maltol shield” that protects the iron as it passes through the stomach, resulting in unprecedented GI tolerability and clinically proven efficacy.2,3

See what sets ACCRUFeR apart.

ACCRUFeR® (ferric maltol) is an FDA approved oral iron treatment for adults with iron deficiency.2

Unprecedented tolerability

In clinical studies, 4.6% of patients taking ACCRUFeR (n=175) discontinued treatment due to adverse gastrointestinal reactions, compared with 2.5% of patients taking a placebo (n=120).2,5,6

About ACCRUFeR
Checkmark icon

Established safety and efficacy

ACCRUFeR achieved FDA approval based on three pivotal studies in patients with ID/IDA associated with chronic inflammation and malabsorption.*,1,5 Among patients taking ACCRUFeR, significant improvements were seen across iron indices, including hemoglobin, ferritin, and TSAT.5,6

Safety and Efficacy
Shield with red plus in the middle icon

Unique “maltol shield”

ACCRUFeR is a non-salt ferric iron uniquely formulated with a “maltol shield” that keeps iron intact as it passes through the stomach. This reduces the likelihood of reactive oxygen species (ROS) formation, which in turn minimizes GI side effects.3,4

Downsides of Oral Iron Salts
Stomach with shield overlay icon

Available at the lowest price possible

We’re committed to making ACCRUFeR accessible for your patients. Eligible patients may pay as little as $0 for ACCRUFeR.

Access and Affordability
Piggy bank icon

About ACCRUFeR

See how ACCRUFeR's "maltol shield" helps minimize gastrointestinal side effects.3,4

Contact Us

Connect with one of our representatives or Medical Information, and sign up for updates from Shield Therapeutics.

References:
1. Schmidt C, Ahmad T, Tulassay Z, et al. Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a phase 3 study. Aliment Pharmacol Ther. 2016;44(3):259-270. doi:10.1111/apt.13665
2. ACCRUFeR® full prescribing information. Shield Therapeutics, 2023.
3. Stallmach A, Büning C. Ferric maltol (ST10): a novel oral iron supplement for the treatment of iron deficiency anemia in inflammatory bowel disease. Expert Opin Pharmacother. 2015;16(18):2859-2867. doi:10.1517/14656566.2015.1096929
4. European Medicines Agency. Accessed March 17, 2021. https://www.ema.europa.eu/en/documents/variation-report/feraccru-h-c-2733-ii-0010-epar-assessment-report-variation_en.pdf.
5. Gasche C, Ahmad T, Zsolt T, et al. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program. Inflamm Bowel Dis. 2015;21:579-588.
6. Pergola PE, Kopyt NP. Oral ferric maltol for the treatment of iron-deficiency anemia in patients with CKD: a randomized trial and open-label extension. Am J Kidney Dis. 2021;78(6):846-
856.e1. doi:10.1053/j.ajkd.2021.03.020
7. Data on file. Shield Therapeutics Inc. 2019.